Consensus Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
7.33 USD -0.14% Intraday chart for Fate Therapeutics, Inc. -1.35% +95.99%

Evolution of the average Target Price on Fate Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e0623c0c7a9b9436d58c.s5Ucy2B0Eg0Q187PgkgeDm26Hx2NQ-h_aIjEOLvM-nY.5KNpnTM4a2tVjqv59T9GYxfNcUvqKpgqOdqNDJaqkiHK3lCgESJgV1-Y-g~d9c2b361794b6a9e425cfd65d03ca904
Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating MT
Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating MT
Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating MT
Mizuho Lowers Price Target on Fate Therapeutics to $8 From $12, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $3 From $5, Maintains Equalweight Rating MT
Wells Fargo Trims Price Target on Fate Therapeutics to $5 From $6, Maintains Equalweight Rating MT
Wedbush Lowers Fate Therapeutics' Price Target to $3 From $6, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $5 From $8, Keeps Equalweight Rating MT
Barclays Adjusts Fate Therapeutics Price Target to $6 From $12, Maintains Overweight Rating MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $5.40 From $6, Maintains Market Perform Rating MT
Wedbush Trims Fate Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating MT
Stifel Nicolaus Adjusts Fate Therapeutics Price Target to $5 From $5.30, Maintains Hold Rating MT
Cantor Fitzgerald Adjusts Price Target on Fate Therapeutics to $5 From $8, Maintains Neutral Rating MT
Wells Fargo Assumes Coverage on Fate Therapeutics With Equal Weight Rating, $6 Price Target MT
Citigroup Adjusts Fate Therapeutics Price Target to $10 From $9, Maintains Buy Rating MT
HC Wainwright Downgrades Fate Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $115 MT
Goldman Sachs Adjusts Price Target on Fate Therapeutics to $4 From $10, Maintains Sell Rating MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $8 From $35, Maintains Equalweight Rating MT
EF Hutton Adjusts Fate Therapeutics' Price Target to $10 From $16, Keeps Buy Rating MT
Stifel Downgrades Fate Therapeutics to Hold From Buy, Adjusts Price Target to $5.30 From $107 MT
BofA Securities Downgrades Fate Therapeutics to Underperform From Buy, Adjusts Price Target to $4 From $72 MT
SVB Securities Adjusts Fate Therapeutics Price Target to $10 From $62, Maintains Outperform Rating MT
Jefferies Adjusts Fate Therapeutics Price Target to $15 From $30, Maintains Buy Rating MT
SMBC Nikko Downgrades Fate Therapeutics to Neutral From Outperform, Adjusts Price Target to $5 From $77 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
7.34 USD
Average target price
7.8 USD
Spread / Average Target
+6.27%
High Price Target
12 USD
Spread / Highest target
+63.49%
Low Price Target
5 USD
Spread / Lowest Target
-31.88%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Fate Therapeutics, Inc.

Morgan Stanley
BMO Capital
Barclays
Wedbush
Mizuho Securities
Wells Fargo Securities
Stifel Nicolaus
Cantor Fitzgerald
Citigroup
HC Wainwright
Goldman Sachs
BofA Securities
EF Hutton
SVB Securities LLC
Jefferies & Co.
SMBC Nikko
Cowen
Piper Sandler
Truist Securities
Guggenheim
Oppenheimer
Canaccord Genuity
Morgan Lewins & Co.
Needham & Co.
Baird
SVB Leerink
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings